American Heart Association Research, In Brief
Outcomes Study Resuscitates Natrecor
You may also be interested in...
Pfizer's Inspra has been a commercial flop, but now a post-marketing study has shown positive results in a broader patient population
The ongoing debate surrounding the safety of Scios' congestive heart failure therapy Natrecor (nesiritide) suggests that FDA should not approve drugs based only on surrogate endpoints, an article published in the July/August 2006 issue of Health Affairs argues
The Johnson & Johnson subsidiary will begin enrollment more than a year after an independent panel recommended the study.